Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2mCRPC 1Triple Negative Breast Neoplasms 1Small Cell Lung Carcinoma 1Recurrence 1Pheochromocytoma 1Paraganglioma 1Ovarian Neoplasms 1Neoplasms 1Neoplasm Metastasis 1Leukemia 1Extensive Stage Lung Small Cell Carcinoma 1Endometrial Neoplasms 1

Interventions

Cyclophosphamide 16fludarabine 9fludarabine phosphate 8Rituximab 5Whole-Body Irradiation 4Peripheral Blood Stem Cell Transplantation 4Mycophenolic Acid 4Melphalan 4Cytarabine 4Busulfan 4Azacitidine 4AP 1903 reagent 4venetoclax 3ruxolitinib 3ibrutinib 3Tacrolimus 3Prednisone 3Methotrexate 3Mesna 3Etoposide 3pegaspargase 2obinutuzumab 2ivosidenib 2Vincristine 2Patient Reported Outcome Measures 2Observation 2Mercaptopurine 2Leucovorin 2Doxorubicin 2Dexamethasone 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Leukemia × talazoparib × Clear all
NCT03974217 2026-02-25

Talazoparib for Cohesin-Mutated AML and MDS With Excess Blasts

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
13 enrolled
Other hematologic neoplasm

Leukemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡